ID: ALA11048
Chembl Id: CHEMBL11048
Cas Number: 85872-58-8
PubChem CID: 135109
Max Phase: Preclinical
Molecular Formula: C14H12N4O4
Molecular Weight: 300.27
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cn1c(=O)c2nc(-c3ccc(C(=O)O)cc3)[nH]c2n(C)c1=O
Standard InChI: InChI=1S/C14H12N4O4/c1-17-11-9(12(19)18(2)14(17)22)15-10(16-11)7-3-5-8(6-4-7)13(20)21/h3-6H,1-2H3,(H,15,16)(H,20,21)
Standard InChI Key: VOGIMZNURUXDIJ-UHFFFAOYSA-N
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
| Molecular Weight: 300.27 | Molecular Weight (Monoisotopic): 300.0859 | AlogP: 0.33 | #Rotatable Bonds: 2 |
| Polar Surface Area: 109.98 | Molecular Species: ACID | HBA: 6 | HBD: 2 |
| #RO5 Violations: ┄ | HBA (Lipinski): 8 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): ┄ |
| CX Acidic pKa: 3.90 | CX Basic pKa: 1.66 | CX LogP: 0.87 | CX LogD: -2.47 |
| Aromatic Rings: 3 | Heavy Atoms: 22 | QED Weighted: 0.71 | Np Likeness Score: -0.65 |
| 1. Hamilton HW, Ortwine DF, Worth DF, Badger EW, Bristol JA, Bruns RF, Haleen SJ, Steffen RP.. (1985) Synthesis of xanthines as adenosine antagonists, a practical quantitative structure-activity relationship application., 28 (8): [PMID:2991519] [10.1021/jm00146a016] |
| 2. Shamim MT, Ukena D, Padgett WL, Daly JW.. (1989) Effects of 8-phenyl and 8-cycloalkyl substituents on the activity of mono-, di-, and trisubstituted alkylxanthines with substitution at the 1-, 3-, and 7-positions., 32 (6): [PMID:2724296] [10.1021/jm00126a014] |
| 3. Daly JW, Padgett W, Shamim MT, Butts-Lamb P, Waters J.. (1985) 1,3-Dialkyl-8-(p-sulfophenyl)xanthines: potent water-soluble antagonists for A1- and A2-adenosine receptors., 28 (4): [PMID:2984420] [10.1021/jm00382a018] |
| 4. Faudone G, Arifi S, Merk D.. (2021) The Medicinal Chemistry of Caffeine., 64 (11.0): [PMID:34019396] [10.1021/acs.jmedchem.1c00261] |
Source(1):
